Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Vitamin D analogues/derivatives | 4427 | 21215-62-3 |
| Dose | Unit | Route |
|---|---|---|
| 100 | U | P |
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.82 hours | Lombardo F, Berellini G, Obach RS |
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 31, 1986 | FDA | NOVARTIS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | H05BA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Calcitonin preparations |
| CHEBI has role | CHEBI:25212 | metabolites |
| CHEBI has role | CHEBI:50646 | antiosteoporotic |
None
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.79 | acidic |
| pKa2 | 9.65 | acidic |
| pKa3 | 11.96 | acidic |
| pKa4 | 12.29 | acidic |
| pKa5 | 12.42 | acidic |
| pKa6 | 12.62 | acidic |
| pKa7 | 12.8 | acidic |
| pKa8 | 12.81 | acidic |
| pKa9 | 12.86 | acidic |
| pKa10 | 12.98 | acidic |
| pKa11 | 13.17 | acidic |
| pKa12 | 13.29 | acidic |
| pKa13 | 13.33 | acidic |
| pKa14 | 13.41 | acidic |
| pKa15 | 13.41 | acidic |
| pKa16 | 13.46 | acidic |
| pKa17 | 13.67 | acidic |
| pKa18 | 13.68 | acidic |
| pKa19 | 13.78 | acidic |
| pKa20 | 13.86 | acidic |
| pKa21 | 13.97 | acidic |
| pKa22 | 10.81 | Basic |
| pKa23 | 7.14 | Basic |
| pKa24 | 6.5 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Calcitonin receptor | GPCR | AGONIST | IC50 | 7.81 | SCIENTIFIC LITERATURE | CHEMBL | |||
| Amylin receptor AMY1 | GPCR | AGONIST | IC50 | 7.53 | SCIENTIFIC LITERATURE | ||||
| Amylin receptor AMY2 | GPCR | AGONIST | IC50 | 8.08 | SCIENTIFIC LITERATURE | ||||
| Amylin receptor AMY3 | GPCR | AGONIST | IC50 | 7.71 | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| C0770558 | UMLSCUI |
| CHEBI:135973 | CHEBI |
| CHEMBL4594248 | ChEMBL_ID |
| DB06773 | DRUGBANK_ID |
| I0IO929019 | UNII |
| 45055432 | PUBCHEM_CID |
| 235481 | RXNORM |
| 002145 | NDDF |
| 127383000 | SNOMEDCT_US |
None